Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway

  • Knut Ketterer
  • , Bo Kong
  • , Dietwalt Frank
  • , Nathalia A. Giese
  • , Andrea Bauer
  • , Jörg Hoheisel
  • , Murray Korc
  • , Jörg Kleeff
  • , Christoph W. Michalski
  • , Helmut Friess

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Neuromedin U (NmU) is a bioactive peptide, ubiquitously expressed in the gastrointestinal tract. Here, we analyzed the role of NmU in pancreatic ductal adenocarcinoma (PDAC) pathogenesis. NmU and NmU receptor-2 mRNA were significantly overexpressed in PDAC and in metastatic tissues. NmU and NmU receptor-2 were localized predominantly in cancer cells. NmU serum levels decreased after tumor resection. Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering. Thus, NmU may be involved in the HGF-c-Met paracrine loop regulating cell migration, invasiveness and dissemination of PDAC.

Original languageEnglish
Pages (from-to)72-81
Number of pages10
JournalCancer Letters
Volume277
Issue number1
DOIs
StatePublished - 8 May 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • c-Met
  • Metastasis
  • Neuromedin U
  • Neuromedin U receptor
  • Pancreatic cancer

Fingerprint

Dive into the research topics of 'Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway'. Together they form a unique fingerprint.

Cite this